ThromboGenics in comfortable position in first profitable year
This article was originally published in Scrip
Executive Summary
ThromboGenicsposted revenues of €30.3 million in its nine-month business update, marking what should be the first profitable year in the company's history. The revenue growth was mainly driven by a €30 million upfront payment from Roche as part of a deal that also included BioInventto develop ThromboGenics' anticancer agent TB-403 (ScripOnline, June 18th, 2008).